All the funding deals in the longevity market
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
The longevity market is attracting investors across biotechnology, diagnostics, preventive healthcare, clinics, nutrition, and consumer health.
We conducted deep research and collected 51 longevity market funding deals announced between 2024 and the second quarter of 2026.
We refresh this page very often to include newly announced longevity market funding deals.
And if you want to better understand this new industry, you should get our beautiful slides covering the longevity market.
Insights
- The 51 longevity market funding deals raised about $3.45 billion in total. This shows strong investor interest across both medical biotechnology and preventive health services.
- Funding reached about $1.92 billion in 2025, compared with approximately $837 million in 2024. Retro Biosciences played a major role with its reported $1 billion round.
- The five largest longevity market deals represented almost 59% of all funding. Large biotechnology rounds therefore had a major effect on the total.
- NewLimit raised $435 million in the second quarter of 2026. The NewLimit deal represented about 63% of all longevity market funding identified for the first half of 2026.
- Several longevity companies raised funding more than once. Loyal, NewLimit, Junevity, GlycanAge, Function Health, Biopeak, and Aeovian Pharmaceuticals all returned to investors for additional capital.
- Longevity biotechnology companies received the largest rounds, but clinics, diagnostics, laboratory testing, nutrition, and consumer products also attracted meaningful investment.
- Preventive health platforms became an important part of the longevity market. Function Health, Prenuvo, Fountain Life, NiaHealth, and Human Longevity raised capital for earlier health detection and monitoring.
- Animal longevity is becoming a funded category of its own. Loyal raised three rounds across the period, including a $100 million Series C in 2026.
This chart, featured in our longevity market deck, illustrates yearly VC funding for longevity startups
Summary table of the funding deals for the longevity market since 2024
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
We focused exclusively on pure players, defined as companies with at least 70–80% of their business directly tied to the longevity market.
Our analysis has been done at a global level with a minimum funding threshold of $300k.
You can also read our detailed analysis to understand how funding activity in the longevity market has evolved recently.
If you want a longer-term view, we also have a study of how funding activity in the longevity market has changed over the years.
Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the longevity market.
| Name | What they do | Amount in $ | Quarter | Source(s) |
|---|---|---|---|---|
| Rapalogix Health | Develops products and therapies that target the biological causes of skin aging | $20.0M | Q2 2026 | PR Newswire |
| NewLimit | Develops medicines that restore healthier function in aging cells through epigenetic reprogramming | $435.0M | Q2 2026 | STAT |
| Life Biosciences | Develops cellular rejuvenation therapies for diseases linked to aging | $80.0M | Q2 2026 | Life Biosciences |
| HexemBio | Develops stem-cell therapies that restore blood and immune function during aging | $10.4M | Q2 2026 | SOSV |
| Loyal | Develops regulated medicines designed to extend healthy lifespan in dogs | $100.0M | Q1 2026 | Business Wire |
| L-Nutra | Develops nutrition programs and medical foods designed to support longevity and healthspan | $36.5M | Q1 2026 | PR Newswire |
| TMRW | Operates longevity clinics offering diagnostics, biological-age testing, and clinical support | $7.0M | Q1 2026 | Longevity.Technology |
| Aeovian Pharmaceuticals | Develops selective mTORC1 medicines for diseases linked to aging biology | $55.0M | Q4 2025 | Business Wire |
| GlycanAge | Measures biological aging and inflammation using glycan biomarkers | $8.7M | Q4 2025 | EU-Startups |
| Junevity | Develops siRNA medicines that reset unhealthy cell behavior linked to aging | $10.0M | Q4 2025 | Business Wire |
| Decode Age | Develops longevity tests and supplements using biomarkers and microbiome science | $1.7M | Q4 2025 | Entrackr |
| Function Health | Provides recurring laboratory tests, health tracking, imaging, and preventive medical insights | $298.0M | Q4 2025 | PR Newswire |
| Blueprint | Offers longevity products, testing, and programs based on Bryan Johnson's health protocol | $60.0M | Q4 2025 | Longevity.Technology |
| NewLimit | Develops epigenetic reprogramming medicines that restore healthier cell function | $45.0M | Q4 2025 | Longevity.Technology |
| Generation Lab | Measures how quickly different body systems are aging through biological testing | $11.0M | Q4 2025 | PR Newswire |
| Fountain Life | Operates longevity clinics using imaging, biomarkers, artificial intelligence, and preventive care | $18.0M | Q3 2025 | TechCrunch |
| Molecular You | Provides biomarker testing and molecular health insights for preventive care | $5.0M | Q3 2025 | GeekWire |
| OneSkin | Develops skincare products that target cellular aging and senescent cells | $20.0M | Q3 2025 | PR Newswire |
| Circulate Health | Provides plasma exchange programs designed to improve healthspan and biological aging | $12.0M | Q3 2025 | PR Newswire |
| NiaHealth | Offers biomarker testing and personalized programs for preventive and long-term health | $5.75M | Q2 2025 | Business Wire |
| Juvenescence | Develops medicines that target age-related diseases and healthy lifespan | $76.0M | Q2 2025 | Juvenescence |
| Biopeak | Operates longevity clinics using diagnostics, imaging, artificial intelligence, and personalized programs | $3.5M | Q2 2025 | Moneycontrol |
| NewLimit | Develops epigenetic reprogramming medicines that restore healthier function in aging cells | $130.0M | Q2 2025 | TechCrunch |
| Junevity | Develops siRNA medicines that restore healthier cell function and improve healthspan | $10.0M | Q1 2025 | Business Wire |
| Cambrian Bio | Develops medicines that target biological causes of aging and age-related disease | $23.0M | Q1 2025 | Channel Point Capital |
| Loyal | Develops regulated medicines designed to extend healthy lifespan in dogs | $22.0M | Q1 2025 | Longevity.Technology |
| Insilico Medicine | Uses generative artificial intelligence and automated laboratories to discover new medicines | $110.0M | Q1 2025 | PR Newswire |
| Retro Biosciences | Develops therapies using cellular reprogramming, autophagy, and plasma-inspired biology | $1,000.0M | Q1 2025 | Longevity.Technology |
| One Bio | Develops plant-fiber technology designed to improve nutrition and long-term health | $27.0M | Q4 2024 | PR Newswire |
| Prenuvo | Provides whole-body MRI screening and preventive health assessments | $120.0M | Q4 2024 | Business Wire |
| Arda Therapeutics | Develops therapies that remove harmful cell populations linked to chronic disease | $43.0M | Q4 2024 | Arda Therapeutics |
| clock.bio | Studies human rejuvenation biology and identifies possible gene-therapy targets | $5.3M | Q4 2024 | Business Wire |
| Integrated Biosciences | Uses synthetic biology and machine learning to develop medicines for age-related diseases | $17.2M | Q4 2024 | Integrated Biosciences |
| Human Longevity, Inc. | Provides preventive longevity care using genomics, diagnostics, and artificial intelligence | $39.8M | Q3 2024 | PR Newswire |
| NADMED | Develops blood tests for NAD and glutathione levels | $3.8M | Q3 2024 | Cision |
| HDAX Therapeutics | Develops HDAC6-targeted medicines for neurological and cardiometabolic diseases | $3.2M | Q3 2024 | HDAX Therapeutics |
| Biopeak | Provides longevity diagnostics, health insights, and personalized clinical programs | $1.43M | Q3 2024 | The Economic Times |
| Oisín Biotechnologies | Develops genetic medicines for frailty, muscle loss, and other age-related conditions | $15.0M | Q3 2024 | Business Wire |
| Function Health | Provides preventive laboratory testing and long-term biomarker tracking | $53.0M | Q2 2024 | PR Newswire |
| Alzheon | Develops oral treatments and diagnostic tests for Alzheimer's disease | $100.0M | Q2 2024 | Alzheon |
| Matter Bio | Develops longevity technologies that protect genome integrity and healthy lifespan | $7.0M | Q2 2024 | PR Newswire |
| Humanaut Health | Operates longevity clinics offering diagnostics, health optimization, and regenerative medicine | $8.7M | Q2 2024 | Business Wire |
| Rubedo Life Sciences | Develops medicines targeting senescent cells that contribute to chronic age-related diseases | $40.0M | Q2 2024 | Business Wire |
| Aeovian Pharmaceuticals | Develops selective mTORC1 medicines for diseases connected to aging biology | $50.0M | Q1 2024 | PR Newswire |
| Loyal | Develops regulated medicines intended to extend healthy lifespan in dogs | $45.0M | Q1 2024 | Business Wire |
| SENISCA | Develops RNA medicines targeting cellular senescence and age-related diseases | $4.7M | Q1 2024 | SENISCA |
| PreemptiveAI | Builds artificial intelligence models that predict health outcomes from biomedical signals | $6.4M | Q1 2024 | PR Newswire |
| GlycanAge | Measures biological age and inflammation using glycan biomarkers | $4.2M | Q1 2024 | EIN Presswire |
| BioAge Labs | Develops metabolic disease treatments based on human aging biology | $170.0M | Q1 2024 | Business Wire |
| Timeline | Develops urolithin A products that support mitochondrial health and healthy aging | $66.0M | Q1 2024 | Timeline |
| Vasa Therapeutics | Develops treatments for cardiovascular aging, frailty, muscle loss, and heart failure | $6.0M | Q1 2024 | Pillsbury |
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Related blog posts
- The latest developments shaping the longevity market
- The most recent news in the longevity market
- How large is the longevity market in reality?
- The most recent funding news in the longevity market
